StockTipsArenaBeta

BUY Thyrocare Technologies Limited — ICICI Securities

BUYThyrocare Technologies Limited
Thyrocare Technologies share price target & all analyst calls

byICICI SecuritiesHorizon: NA (inferred 1 year)30 Oct 2026via Institutional / Brokerage Research

Entry₹456.3Inferred
Target₹620
Total upside +35.88%
Stop lossNot given
CMP₹493.11d ago
Active+8.06%+25.74%upside left 12 mo left
Follow ICICI Securities for new calls(64% target hit, 1085 closed calls)Get alertsWatch THYROCARE for new buy/sell callsGet alertsSee 2 other Long-term calls on THYROCARESee 542 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:23 pm IST
6 supporting7 neutral3 opposing
Supports the BUY call (6)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

Thyrocare Technologies has entered into a share purchase agreement to sell its entire 100% stake in its material subsidiary, Nueclear Healthcare Limited, for an aggregate consideration of Rs 141.4 cro

BSE · Company Update·30 Oct · 1w ago

(opens in new tab)

Thyrocare Technologies reported Q2FY27 consolidated revenue of INR 270.8 crore, up 25.1% YoY, and PAT before exceptional items of INR 60.2 crore, up 25.7% YoY.

BSE · Company Update·29 Oct · 1w ago

(opens in new tab)

Thyrocare Technologies reported Q2FY27 consolidated revenue of INR 270.8 crore, up 25.1% YoY, and PAT before exceptional items of INR 60.2 crore, up 25.7% YoY.

NSE · Press Release·29 Oct · 1w ago

(opens in new tab)

2 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·18 Sept · 2mo ago

Neutral / worth noting (7)

Thyrocare Technologies Limited has entered into a share purchase agreement to sell its entire stake in its wholly owned subsidiary, Nueclear Healthcare Limited.

NSE · Agreements·30 Oct · 1w ago

(opens in new tab)

Please find enclosed outcome of the Board Meeting held on October 29, 2026, inter alia, approving the unaudited financial results for the quarter and half year ended September 30, 2026 ....

BSE · Board Meeting·29 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (3)

Thyrocare Q2 results: Profit falls 68% as ₹45 crore impairment charge weighs on earnings

NewsCnbc-Tv18·29 Oct · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Thyrocare Technologies

All analyst calls on Thyrocare Technologies

More from ICICI Securities

Every call and its outcome